A bill to allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor's previously approved targeted drugs.
The bill’s titles are written by its sponsor.
Sep 15, 2015
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on February 9, 2016, in a previous session of Congress, but was not enacted.
Senator from Colorado
Read Text »
Last Updated: Apr 5, 2016
Length: 10 pages
A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.
Considered by Senate Committee on Health, Education, Labor, and Pensions
A committee held a hearing or business meeting about the bill.
S. 2030 (114th) was a bill in the United States Congress.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
Civic Impulse. (2017). S. 2030 — 114th Congress: Advancing Targeted Therapies for Rare Diseases Act of 2016. Retrieved from https://www.govtrack.us/congress/bills/114/s2030
“S. 2030 — 114th Congress: Advancing Targeted Therapies for Rare Diseases Act of 2016.” www.GovTrack.us. 2015. June 28, 2017 <https://www.govtrack.us/congress/bills/114/s2030>
|title=S. 2030 (114th)
|accessdate=June 28, 2017
|author=114th Congress (2015)
|date=September 15, 2015
|quote=Advancing Targeted Therapies for Rare Diseases Act of 2016